Patent SG-11201810268Y-A (SG)
Title: Combination therapy with notch and pd-1 or pd-l1 inhibitors
Inventor: BENDER MARK HARRATH
IPC: A61K45/06
Filed: 2017-05-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/200969 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 39/395 (2006.01) A61K 31/542 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 45/06 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: Declarations under Rule 4.17: PCT/US2017/032790 — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (22) International Filing Date: — as to the applicant's entitlement to claim the priority of the 16 May 2017 (16.05.2017) earlier application (Rule 4.17(iii)) (25) Filing Language: English Published: — (26) Publication Language: English with international search report (Art. 2 I (3)) (30) Priority Data: 62/339,363 20 May 2016 (20.05.2016) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: BENDER, Mark Harrath; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). GAO, Hong; c/o Eli Lilly and Compa- ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). PATEL, Bharvin Kumar; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agent: DEMETER, John C. et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). Designated States indicated, (81) (unless otherwise for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States indicated, (84) (unless otherwise for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, UG, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, ,_ 1 (54) Title: COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS (57) : The present invention provides medicaments for use in treating and methods of treating T- cell acute lymphoblas- S tic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous cN leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung © cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral 0 squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcino- ei --.... ma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-tri- Ir - fluoro-N-K1S)-2—[[(7S)-5-(2-hydroxyemy1)-6-oxo-7H-pyrido [23-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo- ethyljbutanamide, or 1-1 O a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, ate- el zolizumab, durvalumab, and avelumab. C